Skip to main
HOTH
HOTH logo

Hoth Therapeutics (HOTH) Stock Forecast & Price Target

Hoth Therapeutics (HOTH) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Hoth Therapeutics Inc demonstrates a positive outlook due to its strategic dual-track approach in developing therapies for supportive oncology and metabolic diseases, which may enhance incremental value through its joint venture programs. The company reported that over 65% of participants in its clinical evaluations experienced reductions in pain and pruritus, indicating significant symptom improvement and validating the potential efficacy of its treatments. Additionally, Hoth's second quarter 2025 results reflect effective expense management while concurrently advancing its lead asset, HT-001, into an expanded development pathway, showcasing its operational discipline and growth potential in the biopharmaceutical sector.

Bears say

Hoth Therapeutics Inc reported no revenues for the second quarter of 2025, consistent with expectations, while total operating expenses decreased to $2.2 million from $3.4 million in the previous quarter. The company incurred a net loss of $2.2 million, translating to $(0.17) per share for the quarter, reflecting ongoing financial challenges. This continued absence of revenue generation, coupled with significant operating losses, raises concerns about the company's financial viability and the potential for future growth.

Hoth Therapeutics (HOTH) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hoth Therapeutics (HOTH) Forecast

Analysts have given Hoth Therapeutics (HOTH) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Hoth Therapeutics (HOTH) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hoth Therapeutics (HOTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.